Home / Conditions / GERD Reflux Disease
GERD Reflux Disease: when insurers say no, reviewers often say yes
In 103 published external-review decisions involving gerd reflux disease, independent physician reviewers overturned the insurer’s denial 49.5% of the time.
Published decisions
103
2001–2026
Overturned
49.5%
51 denials reversed
Most-fought treatments for gerd reflux disease
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| GERD Procedure | 59 | 39% |
| Digestion GI Rx | 13 | 69.2% |
| Endoscopy | 10 | 50% |
| Antacids | 3 | 100% |
| Bariatric Surgery | 3 | 66.7% |
| General Anesthesia | 3 | 66.7% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 63 | 34.9% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 40 | 72.5% |
Typical time to a decision
20 days
Most land between 13 and 21 days
Handled as urgent
20.4%
Expedited when a delay would cause harm
Recent direction
Rising
43.5% → 76% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for repeat hepatobiliary iminodiacetic acid (HIDA) scan, repeat impedance test, repeat endoscopy, and/or repeat manometry. Findings: The physician reviewer found that repeat impedance test, repeat endoscopy, and/or repeat manometry. The requested repeat pH-impedance testing is supported as medically necessary for evaluation of this patient. The impedance study can be used to evaluate intra-esophageal liquid movements to assess the patient’s gastroesophageal reflux of acidic and alkaline fluid (Ward, et al.; Cho, et al.). The American College of Gastroenterology (ACG) guidelines for the management of patients with GERD state that reflux monitoring can be performed by pH-impedance testing (Katz, et al.).
Nature of Statutory Criteria/ Case Summary: The enrollee requested coverage for laparoscopic placement of an esophageal sphincter augmentation device (LINX) and cruroplasty. The record indicates the enrollee has gastroesophageal reflux disease and esophagitis. Medications have included ondansetron, famotidine, hycosamine, Dexilant and aluminum magnesium hydroxide. The UGI (upper gastrointestinal series) performed revealed esophageal dysmotility, with increased gastroesophageal junction transit time and a small hiatal hernia without evidence of gastroesophageal reflux. The Bravo pH testing revealed a DeMeester score of 61.5. The findings strongly support a diagnosis of excessive gastroesophageal acid reflux and substantiate an excellent correlation between symptoms of chest pain, regurgitation and reflux of acid.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for laparoscopic anti-reflux surgery utilizing the LINX Reflux Management System.Findings: Two out of three physician reviewers found that the requested laparoscopic anti-reflux surgery utilizing the LINX Reflux Management System is not likely to be more beneficial than any available standard treatment for the patient’s medical condition.Researchers conducted a controlled clinical trial and concluded that sphincter augmentation with the LINX Reflux Management System provided long-term clinical benefits as demonstrated by reduced esophageal acid exposure, improved GERD-related quality of life, and cessation of dependence on PPIs, with minimal side effects and no safety issues.
Nature of Statutory Criteria/Case Summary: The patient has been diagnosed with gastroesophageal reflux disease (GERD)/dysphagia. The patient’s body mass index (BMI) was 25 kg/m². The patient underwent a colonoscopy with propofol as anesthesia. His airway was graded with a Mallampati score of one. The patient’s American Society of Anesthesiologists (ASA) score was one, and there was no documentation of a potentially difficult airway. There is no documentation the patient had previous difficulties or problems with anesthesia. There is no record of any cardiac, pulmonary, renal or hepatic comorbidities. The patient was not on any outpatient medications and did not have any known drug allergies. There is no documentation that the patient had issues with substance abuse or was a smoker. The patient has requested reimbursement for anesthesia CPT-00812 (34 units) for his colonoscopy.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for gerd reflux disease was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.